Product
Bacillus Calmette-Guérin
Aliases
Bacillus Calmette-Guérin (BCG)
6 clinical trials
1 drug
4 indications
Indication
Bladder CancerIndication
Non-Muscle Invasive Bladder CancerIndication
Newborn Vaccine ImmunogenicityIndication
High Risk SuperficialClinical trial
A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCGStatus: Terminated, Estimated PCD: 2023-10-31
Clinical trial
Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder CancerStatus: Recruiting, Estimated PCD: 2025-11-01
Clinical trial
PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDERStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Systems Biology to Identify Biomarkers of Neonatal Vaccine ImmunogenicityStatus: Completed, Estimated PCD: 2022-08-29
Clinical trial
Phase II Study of Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle- Invasive Bladder Cancer (NMIBC) and High- Grade Non-Muscle- Invasive Upper Tract Urothelial Cell Carcinoma (NMI-UTUCC)Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder CancerStatus: Completed, Estimated PCD: 2022-02-24